TY - JOUR
T1 - A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer
AU - Rolston, Kenneth V.I.
AU - Nguyen, Hieu
AU - Amos, Gwendolyn
AU - Eltin, Linda
AU - Fainstein, Victor
AU - Bodey, Gerald P.
PY - 1994/2
Y1 - 1994/2
N2 - In a prospective, randomized, double-blind study comparing teicoplanin and vancomycin for the treatment of gram-positive bacteremias in neutropenic patients, teicoplanin was given at 6 mg/kg of body weight every 24 h intravenously (iv) after initial loading every 12 h for three doses, while vancomycin was administered at 15 mg/kg every 12 h iv. At enrollment, both groups were comparable in age, sex, underlying hematologic or neoplastic disorder, baseline renal functions, and incidence of neutropenia. Treatment was successful in 19 (90%) of 21 patients who received teicoplanin and 24 (96%) of 25 who received vancomycin (P = .58). Adverse reactions occurred more often in the vancomycin group (31%) than in the teicoplanin group (9%; P = .06) and were primarily cutaneous or gastrointestinal. In conclusion, teicoplanin was better tolerated than vancomycin, and no statistically significant difference in efficacy was detected with the sample size in this study.
AB - In a prospective, randomized, double-blind study comparing teicoplanin and vancomycin for the treatment of gram-positive bacteremias in neutropenic patients, teicoplanin was given at 6 mg/kg of body weight every 24 h intravenously (iv) after initial loading every 12 h for three doses, while vancomycin was administered at 15 mg/kg every 12 h iv. At enrollment, both groups were comparable in age, sex, underlying hematologic or neoplastic disorder, baseline renal functions, and incidence of neutropenia. Treatment was successful in 19 (90%) of 21 patients who received teicoplanin and 24 (96%) of 25 who received vancomycin (P = .58). Adverse reactions occurred more often in the vancomycin group (31%) than in the teicoplanin group (9%; P = .06) and were primarily cutaneous or gastrointestinal. In conclusion, teicoplanin was better tolerated than vancomycin, and no statistically significant difference in efficacy was detected with the sample size in this study.
UR - http://www.scopus.com/inward/record.url?scp=0028049058&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028049058&partnerID=8YFLogxK
U2 - 10.1093/infdis/169.2.350
DO - 10.1093/infdis/169.2.350
M3 - Article
C2 - 8106768
AN - SCOPUS:0028049058
SN - 0022-1899
VL - 169
SP - 350
EP - 355
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 2
ER -